Percutaneous balloon compression for the treatment of trigeminal neuralgia: results in 56 patients based on balloon compression pressure monitoring

JEFFREY A. BROWN, M.D., AND JULIE G. PILITSIS, M.D., PH.D.

Department of Neurological Surgery, Wayne State University School of Medicine, Detroit, Michigan

Object. Percutaneous balloon compression is an effective and technically simple method for treating trigeminal neuralgia (TN). Nevertheless, dysesthesias (10–20%) and masseter muscle weakness (66%) following the procedure have been noted. The purpose of this study was to evaluate the results of testing TN with percutaneous balloon compression aided by intraluminal pressure monitoring.

Methods. In this study the authors review the results and complications associated with percutaneous balloon compression by using intraluminal pressure monitoring data obtained in 65 procedures performed in 56 consecutive patients over 4 years. The mean patient age was 71 years (range 37–92 years), and the mean follow-up duration was 17 months (range 3–38 months). The mean intraluminal compression pressure was (1160 ± 62 mm Hg), and the mean duration of compression was 1.15 ± 0.27 minutes. The trigeminal depressor response was observed in 60 (92%) of 65 procedures, and initial pain relief occurred in 92% of patients. The recurrence rate in patients who had initial relief was 16% (nine of 56). The mean time until recurrence in patients who experienced pain relief after surgery was 13 months (range 3–23 months). Mild numbness immediately after surgery was observed in 83% of patients. At the most recent evaluation, 17% of patients reported persistent, nontroublesome numbness and none had moderate or severe numbness. Minor dysesthesia was present in two patients (4%). Mild masseter muscle weakness occurred in 24% of patients and resolved within a maximum period of 1 year. No patient experienced anesthesia dolorosa, corneal keratitis, or other cranial nerve deficits. These morbidity rates are lower than the incidence reported in the literature when pressure monitoring is not used.

Conclusions. These data show that by monitoring compression pressure and limiting the duration of compression, it is possible to reduce the incidence of dysesthesias, severe numbness, and masseter weakness after surgery without increasing the rate of recurrent pain in patients with classic TN.

KEY WORDS • trigeminal neuralgia • trigeminal nerve • pain • compression
CLINICAL MATERIAL AND METHODS

Patient Population

Sixty-five percutaneous balloon compressions were performed in 56 consecutive patients with classic symptoms of unilateral TN between 2000 and 2004. As shown in Table 1, the mean age of the patients was 71 years (range 37–92 years). The mean follow-up duration was 17 months (range 3–38 months). Twenty-three patients (with 36% of the procedures) had undergone previous destructive procedures before their balloon compression. In 10 of 56 patients (with 15% of the procedures) there was first-division pain. Six patients (11%) had multiple sclerosis.

All patients had been treated with carbamazepine or gabapentin for trigeminal pain before being considered for surgery. Preoperative MR imaging with Gd enhancement was routinely performed. When MR imaging was not possible, computerized tomography scans were obtained, with 5-mm slices in the region of the Meckel cave. None of the patients had an associated tumor. The indications for surgery were similar to those for other percutaneous procedures for treatment of TN. Balloon compression was chosen for patients in the following groups: 1) elderly or infirm patients who were at higher risk for morbidity from microvascular decompression; 2) young patients who sought a percutaneous operation with an expectation of minimal postoperative numbness; and 3) those in whom medical therapy failed or who could not tolerate medical therapy with anticonvulsant medications. Preoperative and postoperative data were obtained from review of the medical charts and postoperative questionnaires. Data analysis was performed using commercially available software (SPSS, Inc., Chicago, IL), and a probability value of less than 0.05 was considered statistically significant. The Institutional Review Board at Wayne State University approved this study.

Surgical Technique

Surgery was performed in the operating room, not the radiology suite, with the aid of fluoroscopic imaging. A light general anesthesia was induced, and then an external pacemaker was placed on the patient’s chest. The pacemaker was set to trigger if the heart rate fell below 45 beats/minute and was carefully tested prior to draping. This trigeminal depressor response seen during trigeminal nerve compression consists of both bradycardia and brief hypotension, often with a reflex hypertension emerging after the pacemaker is triggered. Preoperative atropine was not given so that we could use the depressor response as a monitor of trigeminal compression.

Patients were positioned supine, with a roll under their shoulders, allowing approximately 15° of extension. A Food and Drug Administration–approved kit that included an introducing cannula, sharp and blunt obturators, curved and straight guiding styles, and a No. 4 balloon was used to perform the surgery (Cook Vascular, Inc., Leechburg, PA). The 14-gauge introducing cannula was percutaneously passed to the foramen by using Härkel guidelines and aided by lateral fluoroscopic imaging. For third-division pain, the cannula was directed toward the foramen ovale, nearly parallel to the slope of the petrous bone as seen on the lateral image.

A submental view was obtained once the cannula reached the skull base. When the foramen ovale was identified on the fluoroscopic image, the cannula was advanced under repeated, intermittent fluoroscopic guidance by using the submental view. This view provides direct visualization of the foramen ovale. It is easy to feel when the 14-gauge cannula engages the foramen ovale. Often a brief trigeminal depressor response occurs from mechanical compression of the mandibular nerve at the foramen. The cannula should not pass beyond the foramen ovale, and cerebrospinal fluid is not seen when the cannula is properly positioned.

Once the cannula had engaged the foramen ovale, the blunt obturator was removed and a straight guiding stylet inserted. Using the anteroposterior image (with the petrous ridge positioned in the radiographic center of the orbit) the stylet was directed at the medial dip in the petrous bone, which is the proximal entrance to the Meckel cave, the porus trigeminus. The stylet was pointed toward the center of the porus for second- or multidivision pain; to the lateral porus for third-division pain; and to the medial porus for first-division pain. The entrance to the porus is found approximately 17 mm beyond the foramen ovale. The tip of the stylet was set approximately 2 mm beyond the edge of the petrous ridge as seen through the orbit. Once properly positioned, the stylet was withdrawn and the balloon catheter inserted into the same site.

The lateral view of the skull was used during the balloon compression. For second- or third-division pain, the stylet remained parallel and adjacent to the petrous bone. For second- and first-division pain, the stylet was positioned at a more oblique angle relative to the plane of the petrous bone. Once the proper trajectory was established, the stylet was removed. Air was evacuated from the balloon with a tuberculin syringe connected to a three-way stopcock. An insufflation syringe (Merit Medical, Inc., Salt Lake City, UT) was connected to the balloon and used to measure intraluminal pressures in atmospheres of pressure. The balloon was inflated with 0.7 to 0.75 ml of 180 mg% iohexol to reach a target intraluminal compression pressure of 1065

<table>
<thead>
<tr>
<th>TABLE 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristics of 56 patients who underwent percutaneous balloon compression for TN*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>age (yrs)</td>
<td>71.4 ± 10.5</td>
</tr>
<tr>
<td>sex (M/F)</td>
<td>23:33</td>
</tr>
<tr>
<td>disease duration (yrs)</td>
<td>7.5 ± 4.6</td>
</tr>
<tr>
<td>dist most affected/no. of ops</td>
<td>V1: 10/65 (15.4)</td>
</tr>
<tr>
<td></td>
<td>V2: 25/65 (38.5)</td>
</tr>
<tr>
<td></td>
<td>V3: 30/65 (46)</td>
</tr>
<tr>
<td>prior op (%)</td>
<td>38</td>
</tr>
<tr>
<td>MVD</td>
<td>8</td>
</tr>
<tr>
<td>destructive lesioning</td>
<td>54</td>
</tr>
<tr>
<td>time since op (mos)</td>
<td>17.5 ± 7.8</td>
</tr>
<tr>
<td>rate of recurrence (%)</td>
<td>16</td>
</tr>
<tr>
<td>time to recurrence (mos)</td>
<td>12.6 ± 4.6</td>
</tr>
</tbody>
</table>

* Results are expressed as the mean ± standard error of the mean. Abbreviations: dist = distribution; MVD = microvascular decompression.
Balloon compression for trigeminal neuralgia to 1215 mm Hg. Once that pressure was reached and a corresponding pear shape observed, the balloon was left inflated for 1 to 1.5 minutes. The pear shape indicates that the tip of the balloon lies within the porus trigeminus, which is where it must lie to compress the trigeminal nerve adequately. The depressor response may occur at this point, briefly triggering the external pacemaker. Intermittent lateral imaging was obtained to monitor the balloon’s position and shape. The needle and catheter were then removed, and an ice pack and sterile bandage applied to the cheek. The patient was discharged on the day of surgery or the following morning.

RESULTS

Clinical Data

Initial pain relief was attained in 92% of patients. Six patients had minimal or no initial pain relief; four of them had evidence of vascular compression on MR imaging, but had elected to undergo balloon compression as their initial therapy. These patients subsequently underwent microvascular decompression and attained pain relief. The remaining two patients had both a classic electric-shock and a burning, neuropathic component to their pain. This may explain the difficulty in treating them, because there was an element of more atypical pain rather than classic TN.

There were nine recurrences (14%) among the patients who had satisfactory pain relief initially. Subsequent balloon compressions were performed in eight of these nine patients, and pain relief was obtained in all eight. Among the 56 patients, 35% had undergone previous destructive peripheral procedures. This higher incidence of patients who had previously undergone surgery may have led to a higher recurrence rate in this series. Kaplan–Meier survival curves were calculated and the mean time until recurrence was 13 months (Fig. 1).

Immediately after surgery, 83% of patients reported mild numbness. At the most recent postoperative visit, 17% of patients reported persistent numbness. No patient described this numbness as being moderate or severe. Two patients (4%) reported minor dysesthesias. Mild masseter muscle weakness was reported in 24% of patients, and it resolved in all of them in a maximum of 1 year. Neither anesthesia dolorosa nor corneal anesthesia occurred. No other cranial nerve deficits due to compression occurred. No patient suffered aseptic meningitis. There was no significant correlation between the duration of preoperative pain and the likelihood that masseter muscle weakness or sensory dysesthesias would develop.

One death occurred: this patient had undergone previous microvascular decompression, and when pain recurred he underwent balloon compression. He suffered diffuse subarachnoid hemorrhage from a dural arteriovenous fistula found on postoperative angiography studies. This fistula was not evident on the MR image obtained before surgery.

Intraoperative Variables

The mean intraluminal balloon compression pressure was 1160 ± 62 mm Hg. The mean duration of compression was 1.15 ± 0.27 minutes. The depressor response was observed in 60 of 65 procedures. Intraluminal pressure did not significantly affect the development of numbness or masseter muscle weakness (Table 2). There was a nonsignificant trend for patients whose intraluminal pressure was maintained at 1140 to 1216 mm Hg (1.5–1.6 atm) to have a lower incidence of failure or recurrence (chi-square test \( p = 0.1; \) Fig. 2). The presence or absence of the depressor response also did not affect morbidity or recurrence. The duration of compression significantly affected the development of postoperative numbness (\( p < 0.03 \)).

DISCUSSION

Percutaneous balloon compression is a simple and effective treatment for TN that has been used for more than two decades. The rate of pain relief after balloon compression is similar to that reported for radiofrequency thermocoagulation and higher than that associated with glycerol radiosurgery. Balloon compression is especially useful in patients with first-division pain because it does not injure the myelinated fibers that mediate the blink reflex and thus does not lead to corneal keratitis. Masseter muscle weakness, severe numbness, and dysesthesias have been noted, however. Our goal in this series of patients was to produce a trigeminal nerve injury that was

![Fig. 1. Kaplan–Meier analysis of pain recurrence following balloon compression for TN in patients who experienced initial pain relief. The mean time until recurrence was 13 months. Results are expressed as the mean values ± standard error of the mean.](image1)

![Fig. 2. Correlation of patient outcome as related to intraluminal balloon pressure. The intraluminal pressure is expressed in atmospheres (atm).](image2)
Effect of intraoperative variables on patient outcome after percutaneous balloon compression for TN*

<table>
<thead>
<tr>
<th>Variable</th>
<th>Pressure (mm Hg)</th>
<th>Time (mins)</th>
</tr>
</thead>
<tbody>
<tr>
<td>numbness</td>
<td></td>
<td></td>
</tr>
<tr>
<td>present</td>
<td>1550 ± 75</td>
<td>1.18 ± 0.23</td>
</tr>
<tr>
<td>absent</td>
<td>1520 ± 81</td>
<td>1.06 ± 0.10</td>
</tr>
<tr>
<td>p value</td>
<td>0.15</td>
<td>0.03</td>
</tr>
<tr>
<td>maseter weakness</td>
<td></td>
<td></td>
</tr>
<tr>
<td>present</td>
<td>1536 ± 69</td>
<td>1.11 ± 0.18</td>
</tr>
<tr>
<td>absent</td>
<td>1523 ± 85</td>
<td>1.17 ± 0.21</td>
</tr>
<tr>
<td>p value</td>
<td>0.32</td>
<td>0.23</td>
</tr>
<tr>
<td>pain recurrence</td>
<td></td>
<td></td>
</tr>
<tr>
<td>yes</td>
<td>1556 ± 106</td>
<td>1.14 ± 0.19</td>
</tr>
<tr>
<td>no</td>
<td>1528 ± 75</td>
<td>1.15 ± 0.20</td>
</tr>
<tr>
<td>p value</td>
<td>0.29</td>
<td>0.43</td>
</tr>
</tbody>
</table>

* Results are expressed as the mean ± standard error of the mean.

enough to relieve pain consistently, but that limited the occurrence of other complications. By monitoring the compression pressure and modifying its duration, in this study we achieved a rate of pain relief that was comparable to that reported in other studies of balloon compression for TN, but with a lower incidence of dysesthesias, maseter weakness, and severe numbness.

In previous studies of the results of balloon compression for TN, investigators have reported dysesthesias in 10 to 20% of patients and moderate to severe numbness in 20% following this procedure. Masseter muscle weakness has been recognized as common and its incidence is not defined. In a recent review of the literature, Lopez, et al., state that such weakness occurs in nearly 100% of patients. Transient additional cranial nerve deficits, presumably related to overcompression, have been reported in 1.5% of patients.

In our study, dysesthesias occurred in 4% and mild maseter weakness in 24% of patients. No moderate or severe numbness was produced and there were no other cranial nerve deficits. Neither anesthesia dolorosa nor corneal keratitis occurred. Pain relief occurred in 92% of patients. At a mean follow-up duration of 17 months, the recurrence rate was 16%, which is similar or even better than in our previous series. The first author (J.A.B.) performed all operations in both series.

The main difference between this series and previous studies by the first author is the consistent use of a pressure-monitoring device. It was used in a small subset of patients in the last report, but is now used in all cases. The target compression pressure was between 988 and 1368 mm Hg. The resulting tissue compression pressure was estimated to be 750 to 1250 mm Hg. The duration of the compression is also monitored. In the previous series, compressions lasting up to 3 minutes were performed in recurrent cases. In this series, the mean compression time was 1.15 minutes. Our data showed that compression time directly correlated with the development of numbness. Although the pressure data did not reach statistical significance, there was a trend for a better outcome, that is, a lower recurrence rate, in patients whose intraluminal compression pressure measured between 1140 and 1216 mm Hg.

In the last two decades there has been wide variation in the amount and duration of compression pressure used during surgery. For example, pressure measurements between 980 and 2080 mm Hg have been described. One group used a compression time of 3.5 minutes and found that a low pressure resulted in a higher recurrence rate (75%) but fewer side effects (0%), whereas with a higher pressure there were no recurrences at the 1-year follow-up review, but 100% of the patients had side effects. Studies have also been conducted to find the most appropriate pressure. In one study performed in cadavers, researchers found that the mean intraluminal pressure of a Fogarty catheter balloon in the Meckel cave was 1266 ± 80 mm Hg. In a recent study in 62 patients, investigators found that the mean compression pressure of the Fogarty catheter in the Meckel cave was 1204 mm Hg. Although this is less than the compression pressures used in our study, it is probably because the pressure dynamics of the balloon used in the Cook kit and the Fogarty balloon are not comparable. Compression times ranging from 1 to 7 minutes have been reported and sensory loss was subjectively noted to increase with the duration of compression.

Although many groups have documented compression pressure, few have consistently monitored amount of compression, duration of compression, and balloon volume. In a recent study, however, researchers held pressure and volume stable while they altered the total duration of balloon compression. The patients who received compression for 3 minutes had significantly more sensory complaints than the group of patients who had 1 minute of compression. In this study compression pressure, balloon volume, and the duration of balloon compression were all varied. The mean compression time in this study was 1.15 ± 0.21 seconds and the mean pressure was 1520 ± 101 mm Hg. At these values, the patients as a group had a lower rate of side effects and an equal incidence of pain relief, as compared with other series reported in the literature. The recurrence rate is comparable with previous studies, although longer follow-up data are not yet available.

Clinical results in numerous series of patients with TN treated by balloon compression have been published over the last 20 years, and other infrequent complications have been recognized. One case report on balloon compression described a death related to use of a sharp obturator that was passed beyond the foramen ovale into the cavernous sinus. A carotid cavernous fistula and an external carotid fistula have also been reported. These incidents indicate that a cannula with a blunt obturator should be used to reach the foramen ovale through the cheek.

CONCLUSIONS

Percutaneous trigeminal compression continues to be an effective treatment for TN. In this study we have shown that trigeminal compression for 1 to 1.5 minutes with an intraluminal balloon pressure of 1140 to 1215 mm Hg reduces the occurrence of maseter muscle weakness, dysesthesias, and severe numbness without reducing the degree of pain relief achieved in treating patients with classic TN.

Acknowledgment

We acknowledge the assistance of Brookes C. Brown in the preparation of this manuscript.
Balloon compression for trigeminal neuralgia

References


Manuscript received March 15, 2005.
Accepted in final form April 8, 2005.
Address reprint requests to: Jeffrey A. Brown, M.D., Neurological Surgery, P.C., 600 Northern Boulevard #118, Great Neck, New York 11021. email: jbrown@med.wayne.edu.